Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13810-13826

  Villamizar, Olga ^a,c   Chambers, Christopher B ^a   Riberdy, Janice M ^b   Persons, Derek A ^b   Wilber, Andrew ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

Author keywords

Alternative splicing; Apoptosis; Fas; Long noncoding RNA; Saf

Indexed keywords

CELL PROTEIN; FAS ANTIGEN; FAS LIGAND; LONG UNTRANSLATED RNA; MESSENGER RNA; SPLICING FACTOR 45 PROTEIN; UNCLASSIFIED DRUG; FAS PROTEIN, HUMAN; LONG NONCODING RNA FAS-AS1, HUMAN; RBM17 PROTEIN, HUMAN; RNA SPLICING FACTOR;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; EXON; FAS GENE; GENE; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE LOCATION; GENE OVEREXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; PROTEIN RNA BINDING; SAF GENE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SPF45 GENE; TUMOR CELL LINE; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; RNA SPLICING;

APOPTOSIS; FAS RECEPTOR; GENE EXPRESSION REGULATION; HEK293 CELLS; HELA CELLS; HUMANS; RNA SPLICING; RNA SPLICING FACTORS; RNA, LONG NONCODING; RNA, MESSENGER;

EID: 84971657241     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7329     Document Type: Article

References (54)

1. Trauth BC, Klas C, Peters AMJ, Matzuku S, Moller P, Falk W, Debatin KM, and Krammer PH. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science. 1989; 245: 301-5.
2. Yonehara S, Ishii A, and Yonehara M. A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of TNF. J Exp Med. 1989; 169: 1747-56.
3. Suda T and Nagata S. Purification and characterization of the Fas ligand that induces apoptosis. J Exp Med. 1994; 179: 873-9.
4. Morris KV and Mattick JS. The rise of regulatory RNA. Nat Rev Genet. 2014; 15: 423-37.
5. Hu W, Alvarez-Dominguez JR, and Lodish HF. Regulation of mammalian cell differentiation by long non-coding RNAs. EMBO Reports. 2012; 13: 971-83.
6. Rinn JL and Chang HY. Genome regulation by long noncoding RNAs. Ann Rev Biochem. 2012; 81: 145-66.
7. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012; 338: 1435-9.
8. Kung JT, Colognori D, and Lee JT. 2013. Long Noncoding RNAs: Past, Present, and Future. Genetics. 2013; 193: 651-69.
9. Paralkar VR and Weiss MJ. 2013. Long noncoding RNAs in biology and hematopoiesis. Blood. 2013; 121: 4842-6.
10. Li K and Ramchandran R. Natural antisense transcript: a concomitant engagement with protein-coding transcript. Oncotarget. 2010; 1: 447-52. doi: 10.18632/oncotarget.178.
11. Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, Nishida H, Yap CC, Suzuki M, Kawai J, Suzuki H, Carninci P, Hayashizaki Y, et al. Antisense transcription in the mammalian transcriptome. Science. 2005; 309: 1564-6.
12. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, et al. The transcriptional landscape of the mammalian genome. Science. 2005; 309: 1559-63.
13. Nishizawa M, Okumura T, Ikeya Y, and Kimura T. Regulation of inducible gene expression by natural antisense transcripts. Front Biosci (Landmark Ed). 2012; 17: 938-958.
14. Guttman M and Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012; 482: 339-46.
15. Pelechano V and Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet. 2013; 14: 880-93.
16. Brantl S. Regulatory mechanisms employed by cis-encoding antisense RNAs. Curr Opin Microbiol. 2007; 10: 102-9.
17. Chen J, Sun M, Kent WJ, Huang X, Xie H, Wang W, Zhou G, Shi RZ, and Rowley JD. Over 20% of human transcripts might form sense-antisense pairs. Nucleic Acids Res. 2004; 32: 4812-20.
18. Gonzalez I, Munita R, Agirre E, Dittmer TA, Gysling K, Misteli T, and Luco RF. A lncRNA regulates alternative splicing via establishment of a splicing-specific chromatin signature. Nat Struct Mol Biol. 2015; 22: 370-6.
19. Geisler S and Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013; 14: 699-712.
20. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, and Prasanth KV. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010; 39: 925-38.
21. Cascino I, Fiucci G, Papoff G, and Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995; 154: 2706-13.
22. Yan MD, Hong CC, Lai GM, Cheng AL, Lin YW, and Chuang SE. Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas. Hum Mol Genet. 2005; 14: 1465-1474.
23. Batista PJ and Chang HY. Cytotopic localization by long noncoding RNAs. Curr Opin Cell Biol. 2013; 25: 195-199.
24. Alló M, Buggiano V, Fededa JP, Petrillo E, Schor I, de la Mata M, Agirre E, Plass M, Eyras E, Elela SA, Klinck R, Chabot B, and Kornblihtt AR. Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struct Mol Biol. 2009; 16: 717-24.
25. Busch A, Richeter AS, and Backofen R. 2008. IntaRNA: efficient prediction of bacterial sRNA targets incorporating target site accessibility and seed regions. Bioinformatics. 2008; 24: 2849-56.
26. Wright PR, Georg J, Mann M, Sorescu DA, Richter AS, Lott S, Kleinkauf R, Hess WR, and Backofen R. CopraRNA and IntaRNA: predicting small RNA targets, networks and interaction domains. Nucleic Acids Res. 2014; 42: W119-23.
27. Jurica MS, Licklider LJ, Gygi SR, Grigorieff N, and Moore MJ. Purification and characterization of native spliceosomes suitable for three-dimensional structural analysis. RNA. 2002; 8: 426-39.
28. Will CL and Luhrmann R. Spliceosome Structure and Function. Cold Spring Harb Perspect in Biol. 2011; 3: 1-23.
29. Corsini L, Bonnal S, Basquin J, Hothorn M, Scheffzek K, Valcarcel J, and Sattler M. U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. Nat Struct Mol Biol. 2007; 14: 620-9.
30. Liu Y, Conaway L, Rutherford Bethard J, Al-Ayoubi AM, Thompson Bradley, A, Zheng H, Weed SA, and Eblen ST. Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res. 2013; 41: 4949-62.
31. Krystal GW, Armstrong BC, and Battey JF. N-myc mRNA forms an RNA-RNA duplex with endogenous anti-sense transcripts. Mol Cell Biol. 1990; 10: 4180-91.
32. Munroe SH and Lazar MA. Inhibition of c-erbA mRNA splicing by a naturally occuring antisense RNA. J Biol Chem. 1991; 266: 22083-6.
33. Hastings ML, Ingle HA, Lazar MA, and Munroe SH. Post-transcriptional regulation of thyroid hormone receptor expression by cis-acting sequences and a naturally occuring antisense RNA. J Biol Chem. 2000; 275: 11507-13.
34. Beltran M, Puig I, Pena C, Garcia JM, Alvarez AB, Pena R, Bonilla F, and de Herreros AG. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 2008; 22: 756-69.
35. Jolly C and Lakhotia SC. Human sat III and Drosophila hsr omega transcripts: a common paradigm for regulation of nuclear RNA processing in stressed cells. Nucleic Acids Res. 2006; 34: 5508-14.
36. Johnsson P, Ackley A, Vidarsdottir L, Lui WO, Corcoran M, Grandér D, and Morris KV. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol. 2013; 20: 440-6.
37. Graveley BR. Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 2001; 17: 100-7. doi: 10.1016/S0168-9525(00)02176-4
38. Cascino I, Papoff G, Eramo A, and Ruberti G. Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci. 1996; 1: d12-8.
39. Cheng J, Zhou T, Changdan L, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, and Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263: 1759-62.
40. Lu KH, Li W, Liu XH, Sun M, Zhang Ml, Wu WQ, Xie WP, and Hou YY. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 2013; 13: 461.
41. Pickard MR, Mourtada-Maarabouni M, and Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta. 2013; 1832: 1613-23.
42. Zou Y, Jiang Z, Yu X, Sun M, Zhang Y, Zuo Q, Zhou J, Yang N, Han P, Ge Z, De W, and Sun L. Upregulation of Long Noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8SV/neo. PLoS One. 2013; 8: e79598.
43. Wu W, Zhang S, Li X, Xue M, Cao S, and Chen W. 201. Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells. PLoS One. 2013; 8: e73920.
44. Schwerk C and Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell. 2005; 19: 1-13.
45. Izquierdo JM, Majos N, Bonnal S, Martinez C, Castelo R, Guigo R, Bilbao D, and Valcarcel J. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell. 2005; 19: 475-84.
46. Sampath J, Long PR, Shepard RL, Xia X, Devanarayan V, Sandusky GE, Perry 3rd WL, Dantzig AH, Williamson M, Rolfe M, and Moore RE. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am J Pathol. 2003; 163: 1781-90.
47. Al-Ayoubi AM, Zheng H, Liu Y, Bai T, and Eblen ST. Mitogen-activatred protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alterantive splicing site utilization, proliferation and cell adhesion. Mol Cell Biol. 2012; 32: 2880-93.
48. De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E, Riccioni R, Felli N, Samoggia P, and Peschle C. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood. 1999; 93: 796-803.
49. Singer GG and Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity. 1994; 1: 365-71.
50. Inaba H, Komada Y, Li QS, Zhang XL, Tanaka S, Azuma E, Yamamoto H, and Sakurai M. mRNA expression of variant Fas molecules in acute leukemia cells. Am J Hematol. 1999; 62: 150-8.
51. Liu JH, Wei S, Lamy T, Li Y, Epling-Burnette PK, Djeu JY, and Loughran TP, Jr. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 2002; 100: 1449-53.
52. Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, Jackson CE, Puck JM, Dale J, Straus SE, Peter ME, Krammer PH, Fesik S, and Lenardo MJ. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type 1a. Proc Natl Acad Sci USA. 1999; 96: 4552-57.
53. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, and Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010; 329: 689-93.
54. Wilber A, Tschulena U, Hargrove PW, Kim YS, Persons DA, Barbas CF, and Nienhuis AW. A zinc-finger transcriptional activator designed to interact with the beta-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. Blood. 2010; 115: 3033-41.